Atypical antipsychotics for aggression and psychosis in Alzheimer's disease (Q24244504)

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Antipsychotic agents in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Long-Term use of quetiapine in elderly patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

A follow up study of depression in the carers of dementia sufferers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Treating behavioural and psychological signs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Medication use in nursing homes for elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Hallucinations and associated factors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

Keep taking the medicine?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

A structured trial of risperidone for the treatment of agitation in dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003476.PUB2

7 January 2021

10.1002/14651858.CD003476.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16437455

1 reference

Consolidated OpenCitations Corpus – April 2017